Mefenamic acid (Fenamin, Adco-mefenamic Acid, Ponstel Forte, Ponstel, Ponstel S, Dysfem)
Mefenamic acid
Adcock ingram limited
Registration
- Applicant
- Adcock ingram limited
- Certificate holder
- Adcock ingram limited
- Registrations
- 9
- Schedule source
- SAHPRA documentation
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Fenamin - 250 EACH CAPSULE CONTAINS MEFENAMIC ACID 250,0 mg | 250 mgCapsules | 27028127/2.7/0281Approved 17 November 2025 | Registered | Not determined | PIPIL |
| Fenamin - 500 EACH TABLET CONTAINS MEFENAMIC ACID 500 MG | 500 mgTablet | 27028227/2.7/0282Approved 18 August 2023 | Registered | Not determined | PIPIL |
| Fenamin suspension EACH 5 ML SUSPENSION CONTAINS MEFENAMIC ACID 50 MG | 5 mlSuspension | 27028327/2.7/0283Approved 18 August 2023 | Registered | S2 | PIPIL |
| Adco-mefenamic acid 250 MG EACH CAPSULE CONTAINS MEFENAMIC ACID 250,0 mg | 250 mgCapsules | 28001928/2.7/0019Approved 20 January 2022 | Registered | S2 | PIPIL |
| Adco-mefenamic acid 50 mg/5 ML EACH 5,0 ml SUSPENSION CONTAINS MEFENAMIC ACID 50 mg | 50 mg/5 ml | 28022028/2.7/0220 | Registered | Not determined | None |
| Ponstel forte EACH TABET CONTAINS MEFENAMIC ACID 500 mg | Not listed | 28054828/2.7/0548 | Registered | Not determined | None |
| Ponstel 250 EACH CAPSULE CONTAINS MEFENAMIC ACID 250 mg | 250 | 28070328/2.7/0703 | Registered | Not determined | None |
| Ponstel s EACH 5,0 ml SUSPENSION CONTAINS MEFENAMIC ACID 50,0 mg | Not listed | 28070428/2.7/0704 | Registered | Not determined | None |
| Dysfem EACH CAPSULE CONTAINS MEFENAMIC ACID 250,0 mg | Not listed | 36018536/2.7/0185 | Cancelled | Not determined | None |
Regulatory status
Where S2 sits on the scale
A pharmacist can sell it directly, without a prescription.
Schedule 2 medicines sit behind the pharmacy counter. A pharmacist can decide to sell one of these directly, using their own professional judgement, without a doctor's prescription. It can also be dispensed against a prescription like the higher tiers, in which case the usual repeat limits apply. A child under 12 may only be sold a Schedule 2 substance on a prescription, or on a written order that names the purpose and carries a signature the seller recognises. Even though it cannot be advertised to the public in the ordinary sense, its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S2, read from the product's PI-PIL leaflet.
The Consolidated Schedules list this ingredient up to S3; the leaflet's S2 applies to this product.
Who may supply: Only a pharmacist, pharmacist intern or supervised pharmacist's assistant may sell it without a prescription. It may otherwise be dispensed by a pharmacist against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Mefenamic acid
S3: Mefenamic acid
- when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days; and
- preparations containing mefenamic acid as the only therapeutic active substance, when intended for human use only in the treatment of primary dysmenorrhoea subject to a maximum daily dose of 500 millligrams mefenamic acid 3 times a day and a maximum treatment period of 3 days. (S2)
Consolidated Schedules 06 July 2026, lines 3915 to 3921
S2: Mefenamic acid
- when intended for the treatment of post-traumatic conditions, for a maximum treatment period of 5 days; and
- preparations containing mefenamic acid as the only therapeutically active substance, when intended for human use only in the treatment of primary dysmenorrhoea, subject to a maximum daily dose of 500 millligrams 3 times a day and a maximum treatment period of 3 days; (S3)
- except when intended for veterinary use. (S3)
Consolidated Schedules 06 July 2026, lines 2271 to 2280
Pharmacological class: Antipyretics or antipyretic and anti-inflammatory analgesics. (class 2.7)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
2-(2,3-Dimethylanilino)benzoic acid
Drag to rotate. Structure from PubChem CID 4044.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.